EMA Bolsters PRIME Scheme With Improvements

The European Medicines Agency will hold submission readiness meetings with the sponsors of products in the priority medicines scheme around a year ahead of them submitting their marketing authorization applications for regulatory review.

The way forward railway
The PRIME scheme is designed to get medicines for unmet medical needs to patients faster • Source: Shutterstock

The European Medicines Agency is implementing improvements to its PRIME (priority medicines) scheme – introducing a regulatory roadmap and product development tracker, providing expedited scientific advice, and holding submission readiness meetings to help avoid the submission of premature marketing applications.

PRIME was launched in 2016 to help speed up the development and regulatory review of medicines for unmet medical needs...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

More from Geography

Could Study Questioning GLP-1 Cost Savings Impact CMMI Demo Chances?

 
• By 

The findings are consistent with some other research and likely are due to obesity patients becoming more connected to needed health care services.

Why Chiesi’s Raxone Faced A Decade-Long Wait For English Funding

 

Chiesi’s orphan drug Raxone has secured an English funding recommendation for the treatment of Leber's hereditary optic neuropathy, a decade after the orphan drug was approved for marketing. Chiesi told the Pink Sheet about its “long, and often challenging” road to reimbursement.

Europe Eyes First Therapies For PSC And cALD In Latest EMA Drug Filings

 

Norucholic acid and leriglitazone, for treating primary sclerosing cholangitis and cerebral adrenoleukodystrophy, respectively, are among 12 new drugs that the European Medicines Agency has started to review for potential EU marketing approval.